Delving into the Latest Updates on Pieris Australia Pty Ltd. with Synapse

概览

排名前五的药物类型	数量

小分子化药	1

排名前五的靶点	数量

CTGF(结缔组织生长因子)	1

关联

1

项与 Pieris Australia Pty Ltd. 相关的药物

PRS-220

靶点

CTGF

作用机制

CTGF抑制剂

在研机构

Pieris Australia Pty Ltd.

原研机构

Pieris Pharmaceuticals, Inc.

在研适应症

特发性肺纤维化

非在研适应症-

最高研发阶段临床1期

首次获批国家/地区-

首次获批日期-

3

项与 Pieris Australia Pty Ltd. 相关的临床试验

NCT05473533

/ Completed临床1期

A Phase 1, Randomized, Blinded, Placebo Controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of PRS 220 Administered by Oral Inhalation in Healthy Subjects.

A dose escalating study of PRS-220 administered by oral inhalation in healthy subjects

开始日期2022-10-31

申办/合作机构

Pieris Australia Pty Ltd.

NCT03574805

/ Completed临床1期

A Dose-Escalating, Single-Blind Study to Assess the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of PRS-060 Administered by Oral Inhalation in Subjects With Mild Asthma

Study of Multiple Doses of PRS-060 Administered by Oral Inhalation in Subjects with Mild Asthma

开始日期2018-06-26

申办/合作机构

Pieris Australia Pty Ltd.

NCT03384290

/ Completed临床1期

A Dose Escalating Single Blind Study to Assess the Safety, Tolerability and Pharmacokinetics of a Single Dose of PRS-060 Administered by Oral Inhalation or IV Infusion in Healthy Subjects

A Dose Escalating Study of PRS-060 Administered by Oral Inhalation or IV Infusion in Healthy Subjects

开始日期2017-12-08

申办/合作机构

Pieris Australia Pty Ltd.

100 项与 Pieris Australia Pty Ltd. 相关的临床结果

登录后查看更多信息

0 项与 Pieris Australia Pty Ltd. 相关的专利（医药）

登录后查看更多信息

100 项与 Pieris Australia Pty Ltd. 相关的药物交易

登录后查看更多信息

100 项与 Pieris Australia Pty Ltd. 相关的转化医学

登录后查看更多信息